Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF

Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression. The post Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder…

Read More

SOAR Act Would Help Individuals Relying on Oxygen Thrive

The bill clarifies very specific patient protections and codifies a Patient’s Bill of Rights, all of which would ensure that individuals receiving supplemental oxygen in the home – and their suppliers – understand requirements around equipment, communications, and care options.  The post SOAR Act Would Help Individuals Relying on Oxygen Thrive appeared first on MedCity…

Read More

Hospitals Leaders Share How They’re Balancing Finance, Innovation and Patient Care

During a recent panel, hospital leaders discussed how they approach the balancing act between innovation and financial sustainability. They shared tactics such as reassessing vendor contracts, leaning into existing tech capabilities and finding creative ways to support patients without compromising margins. The post Hospitals Leaders Share How They’re Balancing Finance, Innovation and Patient Care appeared…

Read More